Management of surgical hemostasis: Systemic agents

Vascular

Volumn 16, Issue SUPPL. 1, 2008, Pages

  Levy, Jerrold H ^a   Tanaka, Kenichi A ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Anticoagulation; Antifibrinolytics; Aprotinin; Bleeding; Cardiac surgery; Desmopressin; Hemostasis; Protamine; Recombinant factor VIIa; Surgery

Indexed keywords

AMINOCAPROIC ACID; ANTIFIBRINOLYTIC AGENT; APROTININ; DESMOPRESSIN; FIBRINOGEN; PLACEBO; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

ADVERSE DRUG REACTION; ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; CARDIOPULMONARY BYPASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART RIGHT VENTRICLE FAILURE; HEART SURGERY; HEMOSTASIS; HUMAN; INCREASED DEATH RISK; KIDNEY FAILURE; LUNG VASOCONSTRICTION; MORTALITY; PERIOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VON WILLEBRAND DISEASE;

EID: 44349105418     PISSN: 17085381     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med 2007;356:2301-11.
2. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004;44:1143-8.
3. Spiess BD. Risks of transfusion: outcome focus. Transfusion 2004;44(12 Suppl):4S-14S.
4. Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth 2004;8:267-81.
5. Levy JH. Massive transfusion coagulopathy. Semin Hematol 2006;43(1 Suppl 1):S59-63.
6. Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004;44:1453-62.
7. Despotis GJ, Zhang L, Lublin DM. Transfusion risks and transfusion-related pro-inflammatory responses. Hematol Oncol Clin North Am 2007;21:147-61.
8. Levy JH, Tanaka KA, Steiner ME. Evaluation and management of bleeding during cardiac surgery. Curr Hematol Rep 2005;4:368-72.
9. Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Ferraris SP, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg 2007;83(5 Suppl):S27-86.
10. Levy JH, Tanaka KA. The anticoagulated patient: strategies for effective blood loss management. Surgery 2007;142(4 Suppl):S71-7.
11. Despotis GJ, Goodnough LT. Management approaches to platelet-related microvascular bleeding in cardiothoracic surgery. Ann Thorac Surg 2000;70(2 Suppl):S20-32.
12. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266-73.
13. Levy JH. Hemostatic agents. Transfusion 2004;44(12 Suppl):58S-62S.
14. Levy JH. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. Am J Health Syst Pharm 2005;62(12 Suppl):S15-9.
15. Royston D, Chhatwani A. Safety aspects of aprotinin therapy in cardiac surgery patients. Expert Opin Drug Saf 2006;5:539-52.
16. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
17. Henry DA, Moxey AJ, Carless PA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2001;CD001886. Ed: Cochrane Database Syst Rev. 2001;(1):CD001886. Review Update in: Cochrane Database syst Rev. 2007:(4):CD001886,
18. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
19. Mangano DT, Tudor IC, Dietzel C, et al. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65.
20. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007;297:471-9.
21. US Food and Drug Administration. Available at: http://www.fda.gov/cder/ drug/early_comm/aprotinin.htm.
22. US Food and Drug Administration. Available at: http://www.fda.gov/bbs/ topics/NEWS/2007/NEW01738.html.
23. Levi MM, Vink R, de Jonge E. Management of bleeding disorders by prohemostatic therapy. Int J Hematol 2002;76 Suppl 2:139-44.
24. Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006;202:216-22.
25. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-operative Transfusion (ISPOT) Investigators. Anesth Analg 1997;85:1258-67.
26. Wells PS. Safety and efficacy of methods for reducing perioperative allogeneic transfusion: a critical review of the literature. Am J Ther 2002;9:377-88.
27. Zufferey P, Merquiol F, Laporte S, et al. Do antifibrinolytics reduce allogeneic blood transfusion in orthopedic surgery? Anesthesiology 2006;105:1034-46.
28. Levy JH, Adkinson NF. Anaphylaxis during cardiac surgery: implications for clinicians. Anesth Analg 1986;65:739-42.
29. Levy JH, Zaidan JR, Faraj B. Prospective evaluation of risk of protamine reactions in patients with NPH insulin-dependent diabetes. Anesth Analg 1986;65:739-42.
30. Levy JH, Schwieger IM, Zaidan JR, et al. Evaluation of patients at risk for protamine reactions. J Thorac Cardiovasc Surg 1989;98:200-4.
31. Mannucci PM. Treatment of von Willebrand's disease. N Engl J Med 2004;351:683-94.
32. Mannucci PM. Hemostatic drugs. N Engl J Med 1998;339:245-53.
33. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood 1997;90:2515-21.
34. Federici AB, Mannucci PM. Management of inherited von Willebrand disease in 2007. Ann Med 2007;39:346-58.
35. Frankville DD, Harper GB, Lake CL, Johns RA. Hemodynamic consequences of desmopressin administration after cardiopulmonary bypass. Anesthesiology 1991;74:988-96.
36. Rocha E, Llorens R, Páramo JA, et al. Does desmopressin acetate reduce blood loss after surgery in patients on cardiopulmonary bypass? Circulation 1988;77:1319-23.
37. Salzman EW, Weinstein MJ, Reilly D, Ware JA. Adventures in hemostasis. Desmopressin in cardiac surgery. Arch Surg 1993;128:212-7.
38. Salzman EW, Weinstein MJ, Weintraub RM, et al. Treatment with desmopressin acetate to reduce blood loss after cardiac surgery. A double-blind randomized trial. N Engl J Med 1986;314:1402-6.
39. Weinstein M, Ware JA, Troll J, Salzman E. Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate. Blood 1988;71:1648-55.
40. de Prost D, Barbier-Boehm G, Hazebroucq J, et al. Desmopressin has no beneficial effect on excessive postoperative bleeding or blood product requirements associated with cardiopulmonary bypass. Thromb Haemost 1992;68:106-10.
41. Mannucci PM, Carlsson S, Harris AS. Desmopressin, surgery and thrombosis. Thromb Haemost 1994;71:154-5.
42. Nielsen VG, Levy JH. Fibrinogen and bleeding: old molecule - new ideas. Anesth Analg 2007;105:902-3.
43. Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005;93:1101-7.
44. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. J Thromb Haemost 2007;5:266-73.
45. Steiner ME, Key NS, Levy JH. Activated recombinant factor VII in cardiac surgery. Curr Opin Anaesthesiol 2005;18:89-92.
46. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood 2004;104:3858-64.
47. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest 1993;92:1207-12.
48. Butenas S, Brummel KE, Branda RF, et al. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood 2002;99:923-30.
49. Levy JH, Fingerhut A, Brott T, et al. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile. Transfusion 2006;46:919-33.
50. O'Connell KA, Wood JJ, Wise RP, et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006;295:293-8.
51. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion 2004;44:1325-31.